TY  - CONF
AU  - Capdevila, J.
AU  - Teule, A.
AU  - Lopez, C.
AU  - Garcia-Carbonero, R.
AU  - Benavent, M.
AU  - Custodio, A.
AU  - Cubillo, A.
AU  - Alonso, V.
AU  - Alonso-Gordoa, T.
AU  - Carmona-Bayonas, A.
AU  - Crespo, G.
AU  - Blanco-Codesido, M.
AU  - Jimenez-Fonseca, P.
AU  - Viudez, A.
AU  - La Casta Munoa, A.
AU  - Sevilla, I.
AU  - Llanos, M.
AU  - Segura, A.
AU  - Hernando-Cubero, J.
AU  - Manzano, J. L.
PY  - 2020
DO  - 10.1016/j.annonc.2020.08.1373
SN  - 0923-7534
UR  - https://hdl.handle.net/10668/26985
T2  - Annals of oncology
AB  - BackgroundImmune checkpoint blockade (ICB) has demonstrated limited activity in advanced NENs mainly due to the background biology of these “cold” neoplasms, with low tumor mutational burden, expression of PD-L1 and lymphocyte infiltration. Targeting...
LA  - en
PB  - Elsevier
KW  - durvalumab
KW  - B7-H1 Antigen
KW  - Survival Rate
KW  - Carcinoid Tumor
KW  - Lymphocytes
KW  - tremelimumab
KW  - CTLA-4 Antigen
KW  - Lung Neoplasms
KW  - Lung
KW  - Biology
TI  - A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
TY  - conference output
VL  - 31
ER  -